{"title":"CD169<sup>+</sup> Macrophages Residing in the Draining Lymph Nodes and Infiltrating the Tumor Play Opposite Roles in the Pathogenesis of Bladder Cancer.","authors":"Masakazu Nagata, Kazuhiro Ishizaka, Touko Asano","doi":"10.2147/RRU.S384113","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose: </strong>CD169<sup>+</sup> macrophages are considered to enhance anti-tumor immunity by capturing lymph-borne dead tumor cells. The number of CD169<sup>+</sup> macrophages in regional lymph nodes (RLNs) is positively correlated with prolonged cancer-free survival in various human cancers. However, a recent study argued against this dogma; that is, CD169<sup>+</sup> macrophages infiltrating into the tumor were associated with poor prognosis in patients with breast cancer. To explain this discrepancy, we quantified the number of CD169<sup>+</sup> macrophages located in the bladder tumor and RLNs of the same patients and examined their relationship with the 5-year survival rate.</p><p><strong>Patients and methods: </strong>Tumor and RLN specimens resected from 40 invasive bladder cancer patients (29 males and 11 females; median age, 70.7 years; range, 49-81 years) who underwent radical cystectomy were evaluated using immunostaining.</p><p><strong>Results: </strong>The number of CD169<sup>+</sup> macrophages in RLNs was associated with a good cancer prognosis, while CD169<sup>+</sup> macrophages infiltrating the tumor strongly correlated with a higher incidence of lymphovascular invasion.</p><p><strong>Conclusion: </strong>CD169<sup>+</sup> macrophages play opposing roles in the induction of anti-tumor immunity based on their location in RLNs or tumors.</p>","PeriodicalId":21008,"journal":{"name":"Research and Reports in Urology","volume":"15 ","pages":"1-7"},"PeriodicalIF":2.0000,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/3b/d5/rru-15-1.PMC9843471.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Research and Reports in Urology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2147/RRU.S384113","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"UROLOGY & NEPHROLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Purpose: CD169+ macrophages are considered to enhance anti-tumor immunity by capturing lymph-borne dead tumor cells. The number of CD169+ macrophages in regional lymph nodes (RLNs) is positively correlated with prolonged cancer-free survival in various human cancers. However, a recent study argued against this dogma; that is, CD169+ macrophages infiltrating into the tumor were associated with poor prognosis in patients with breast cancer. To explain this discrepancy, we quantified the number of CD169+ macrophages located in the bladder tumor and RLNs of the same patients and examined their relationship with the 5-year survival rate.
Patients and methods: Tumor and RLN specimens resected from 40 invasive bladder cancer patients (29 males and 11 females; median age, 70.7 years; range, 49-81 years) who underwent radical cystectomy were evaluated using immunostaining.
Results: The number of CD169+ macrophages in RLNs was associated with a good cancer prognosis, while CD169+ macrophages infiltrating the tumor strongly correlated with a higher incidence of lymphovascular invasion.
Conclusion: CD169+ macrophages play opposing roles in the induction of anti-tumor immunity based on their location in RLNs or tumors.
期刊介绍:
Research and Reports in Urology is an international, peer-reviewed, open access, online journal. Publishing original research, reports, editorials, reviews and commentaries on all aspects of adult and pediatric urology in the clinic and laboratory including the following topics: Pathology, pathophysiology of urological disease Investigation and treatment of urological disease Pharmacology of drugs used for the treatment of urological disease Although the main focus of the journal is to publish research and clinical results in humans; preclinical, animal and in vitro studies will be published where they will shed light on disease processes and potential new therapies. Issues of patient safety and quality of care will also be considered.